{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:42:46Z","timestamp":1793320966196,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clindermatol.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:09:21Z","timestamp":1770998961000},"page":"212-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vitamins and the skin: Vitamin A and retinoids in dermatology"],"prefix":"10.1016","volume":"44","author":[{"given":"Clio","family":"Dessinioti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Katsambas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.02.005_bib0001","series-title":"European Handbook of Dermatological Treatments","first-page":"1741","article-title":"Retinoids","author":"Saurat","year":"2023"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molcel.2005.03.026","article-title":"A ligand-activated nuclear localization signal in cellular retinoic acid binding protein-II","volume":"18","author":"Sessler","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.det.2015.05.007","article-title":"The role of systemic retinoids in the treatment of cutaneous T-cell lymphoma","volume":"33","author":"Huen","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0076-6879(90)90005-L","article-title":"Vitamin A-mediated regulation of keratinocyte differentiation","volume":"190","author":"Giudice","year":"1990","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.clindermatol.2010.03.029","article-title":"Syndromes associated with nutritional deficiency and excess","volume":"28","author":"Jen","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0006","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1067\/S0190-9622(03)01564-0","article-title":"Oral retinoid therapy for dermatologic conditions in children and adolescents","volume":"49","author":"Brecher","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0007","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archderm.137.12.1597","volume":"137","author":"Kang","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0008","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archderm.143.5.606","article-title":"Improvement of naturally aged skin with vitamin A (retinol)","volume":"143","author":"Kafi","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0009","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJM199305203282002","article-title":"Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients","volume":"328","author":"Bulengo-Ransby","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJM199308193290803","article-title":"Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid)","volume":"329","author":"Griffiths","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0011","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1523-1747.2000.00902.x","article-title":"Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin","volume":"114","author":"Varani","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0012","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2005.06.052","article-title":"Long-term treatment of photoaged human skin with topical retinoic acid improves epidermal cell atypia and thickens the collagen band in papillary dermis","volume":"53","author":"Cho","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0013","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamadermatol.2022.1891","article-title":"Biomarkers of tretinoin precursors and tretinoin efficacy in patients with moderate to severe facial photodamage: a randomized clinical trial","volume":"158","author":"Chien","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2026.02.005_bib0014","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/bjd\/ljad282","article-title":"Skin ageing and topical rejuvenation strategies","volume":"189","author":"Griffiths","year":"2023","journal-title":"Br J Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2026.02.005_bib0015","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/jdv.13776","article-title":"European evidence-based (S3) guideline for the treatment of acne: update 2016: short version","volume":"30","author":"Nast","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0016","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1111\/jdv.16430","article-title":"Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin","volume":"34","author":"Dessinioti","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0017","article-title":"Acne vulgaris","volume":"1","author":"Moradi Tuchayi","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"suppl","key":"10.1016\/j.clindermatol.2026.02.005_bib0018","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mjd.2003.618","article-title":"Management of acne: a report from a Global Alliance to Improve Outcomes in Acne","volume":"49","author":"Gollnick","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11154-016-9389-5","article-title":"Beyond acne: current aspects of sebaceous gland biology and function","volume":"17","author":"Zouboulis","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0020","first-page":"429","article-title":"Antibiotics and antimicrobial resistance in acne: epidemiological trends and clinical practice considerations","volume":"95","author":"Dessinioti","year":"2022","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13555-023-01079-8","article-title":"The microbiome and acne: perspectives for treatment","volume":"14","author":"Dessinioti","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0022","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jid.2018.09.023","article-title":"Skin ecology during sebaceous drought\u2014how skin microbes respond to isotretinoin","volume":"139","author":"McCoy","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0023","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris\u2014part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0024","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0025","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0026","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2012.07.013","article-title":"Acitretin for the treatment of cutaneous T-cell lymphoma","volume":"68","author":"Cheeley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0027","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000512484","article-title":"Evaluation of alitretinoin for the treatment of mycosis fungoides and Sezary syndrome","volume":"237","author":"Alhusayen","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0029","unstructured":"iPLEDGE REMS (Risk Evaluation and Mitigation Strategy). Available at: https:\/\/ipledgeprogram.com\/#Main. Accessed January 4, 2024."},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0030","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/archderm.1995.01690210067011","article-title":"Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. a double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams","volume":"131","author":"Griffiths","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0031","unstructured":"European Medicines Evaluation Agency (EMEA). Targretin (bexarotene) annex I: summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/targretin-epar-product-information_en.pdf. Accessed January 2, 2024."},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0032","unstructured":"European Medicines Evaluation Agency (EMEA). Isotretinoin. annex III: summary of product characteristics. Available at. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/roaccutane-article-30-referral-annex-i-ii-iii_en.pdf. Accessed on May 19, 2019."},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0033","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/ced.15382","article-title":"Retinoid-induced skeletal hyperostosis in disorders of keratinization","volume":"47","author":"Doolan","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0034","first-page":"111","article-title":"Acne therapy with tretinoin in combination with antibiotics","volume":"74","author":"Kligman","year":"1975","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0035","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.4049\/jimmunol.174.5.2467","article-title":"Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function","volume":"174","author":"Liu","year":"2005","journal-title":"J Immunol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2026.02.005_bib0036","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0926-9959(98)00087-7","article-title":"Immunomodulatory effects of tretinoin in combination with clindamycin","volume":"11","author":"Wauben-Penris","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0037","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/edm.12.44","article-title":"Fixed-dose combination gel clindamycin 1.2%\/tretinoin 0.025% for the treatment of acne vulgaris: a review","volume":"7","author":"Dessinioti","year":"2012","journal-title":"Expert Rev Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2026.02.005_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","article-title":"European evidence-based (S3) guidelines for the treatment of acne","volume":"26","author":"Nast","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0039","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1517\/14656566.9.16.2931","article-title":"Clindamycin phosphate\/tretinoin gel formulation in the treatment of acne vulgaris","volume":"9","author":"Abdel-Naser","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1468-3083.1998.tb00974.x","article-title":"Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne","volume":"11","author":"Richter","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2026.02.005_bib0041","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0926-9959(98)00091-9","article-title":"Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel in acne vulgaris","volume":"11","author":"Cambazard","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0042","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaad.2005.04.046","article-title":"Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin\/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris","volume":"54","author":"Leyden","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0043","series-title":"European Handbook of Dermatological Treatments","first-page":"651","article-title":"Melasma","author":"Dessinioti","year":"2023"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0044","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jama.1982.03320380006003","article-title":"Synthetic vitamin A analogue (isotretinoin) awaiting approval for cystic acne therapy","volume":"247","author":"Macek","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0045","unstructured":"European Medicines Agency (\u0395\u039c\u0395\u0391). Isotretinoin. annex I, II, III. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/roaccutane-article-30-referral-annex-i-ii-iii_en.pdf. Accessed May 19, 2019."},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0046","unstructured":"European Directive for systemic isotretinoin prescription. EMEA-Committee for Proprietary Medicinal Products (CPMP); 2003."},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0047","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jdv.19477","article-title":"Isotretinoin-associated acne fulminans: a multicentre, retrospective study of the European Academy of Dermatology and Venereology Task Force on Acne, Rosacea and Hidradenitis Suppurativa","volume":"38","author":"Dessinioti","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0048","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.clindermatol.2016.10.005","article-title":"Difficult and rare forms of acne","volume":"35","author":"Dessinioti","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0049","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bjd.15843","article-title":"Guidelines for the management of acne: recommendations from a French multidisciplinary group","volume":"177","author":"Le Cleach","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0051","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjd.15668","article-title":"Efficacy and adverse events of oral isotretinoin for acne: a systematic review","volume":"178","author":"Vallerand","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0052","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/13543784.17.3.437","article-title":"Alitretinoin: a comprehensive review","volume":"17","author":"Cheng","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0053","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/cod.14035","article-title":"Guidelines for diagnosis, prevention, and treatment of hand eczema","volume":"86","author":"Thyssen","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0054","first-page":"1054","article-title":"S2k guideline diagnosis, prevention, and therapy of hand eczema","volume":"21","author":"Bauer","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0055","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2133.2009.09572.x","article-title":"Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema","volume":"162","author":"Bissonnette","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0056","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2230.2012.04396.x","article-title":"Extended treatment with oral alitretinoin for patients with chronic hand eczema not fully responding to initial treatment","volume":"37","author":"Lynde","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0057","unstructured":"Toctino (alitretinoin) 10 mg soft capsules. summary of product characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/6364\/smpc\/print. Accessed January 2, 2024."},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0058","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jdv.12684","article-title":"Treatment of cutaneous T-cell lymphoma with oral alitretinoin","volume":"29","author":"Kapser","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0059","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1002\/cam4.4237","article-title":"Alitretinoin in the treatment of cutaneous T-cell lymphoma","volume":"10","author":"Kaemmerer","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0060","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.18472","article-title":"Efficacy of oral alitretinoin in treatment of mycosis fungoides palmaris et plantaris","volume":"103","author":"Jeong","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0061","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjd.17625","article-title":"Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review","volume":"181","author":"Mason","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0062","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis","volume":"30","author":"D\u00e1vila-Seijo","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0063","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/bjd\/ljad004","article-title":"Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR","volume":"188","author":"Alabas","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0064","first-page":"1478","article-title":"Darier and Hailey-Hailey disease: update 2021","volume":"19","author":"Rogner","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.17709","article-title":"Epidemiology of advanced cutaneous squamous cell carcinoma","volume":"36","author":"Dessinioti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0066","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. part 1: diagnostics and prevention-update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0067","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0190-9622(99)70359-2","article-title":"Acitretin in psoriasis: an overview of adverse effects","volume":"41","author":"Katz","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0068","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0069","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0070","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s13555-022-00824-9","article-title":"Matching-adjusted indirect comparison of long-term efficacy and safety outcomes for calcipotriol plus betamethasone dipropionate foam versus halobetasol proprionate plus tazarotene lotion in the treatment of plaque psoriasis","volume":"12","author":"Adam","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0071","first-page":"256","article-title":"Tazarotene versus tazarotene plus clindamycin\/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial","volume":"5","author":"Tanghetti","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0072","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.clinthera.2004.11.012","article-title":"Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials","volume":"26","author":"Shalita","year":"2004","journal-title":"Clin Ther"},{"issue":"suppl","key":"10.1016\/j.clindermatol.2026.02.005_bib0073","first-page":"4","article-title":"Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial","volume":"67","author":"Webster","year":"2001","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0074","first-page":"542","article-title":"A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris","volume":"18","author":"Tanghetti","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.36849\/JDD.2020.3977","article-title":"Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials","volume":"19","author":"Tanghetti","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0076","doi-asserted-by":"crossref","first-page":"272","DOI":"10.36849\/JDD.2020.4869","article-title":"Novel polymeric lotion formulation of once-daily tazarotene (0.045%) for moderate-to-severe acne: pooled phase 3 analysis","volume":"19","author":"Tanghetti","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0077","doi-asserted-by":"crossref","first-page":"727","DOI":"10.36849\/JDD.2020.5125","article-title":"Novel polymeric tazarotene 0.045% lotion for moderate-to-severe acne: pooled phase 3 analysis by race\/ethnicity","volume":"19","author":"Bhatia","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0078","doi-asserted-by":"crossref","first-page":"602","DOI":"10.36849\/JDD.2020.4959","article-title":"New polymeric once-daily tazarotene 0.045% lotion formulation for moderate-to-severe acne: pooled phase 3 pediatric analysis","volume":"19","author":"Eichenfield","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0079","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2022.2147391","article-title":"Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin","volume":"34","author":"Tanghetti","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0080","first-page":"783","article-title":"Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris","volume":"10","author":"Tanghetti","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"suppl 4","key":"10.1016\/j.clindermatol.2026.02.005_bib0081","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jdv.13195","volume":"29","author":"Gollnick","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0082","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/jdv.14726","article-title":"A cross-sectional study of clinical factors associated with acne facial scarring in patients with active acne","volume":"32","author":"Dessinioti","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0083","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13555-018-0231-8","article-title":"Adapalene 0.3% gel shows efficacy for the treatment of atrophic acne scars","volume":"8","author":"Loss","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0084","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/jdv.14026","article-title":"Adapalene 0.1%\/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial","volume":"31","author":"Dreno","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-018-0352-y","article-title":"Prevention and reduction of atrophic acne scars with adapalene 0.3%\/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison","volume":"19","author":"Dr\u00e9no","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0086","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40257-019-00454-6","article-title":"Long-term effectiveness and safety of up to 48 weeks\u2019 treatment with topical adapalene 0.3%\/benzoyl peroxide 2.5% gel in the prevention and reduction of atrophic acne scars in moderate and severe facial acne","volume":"20","author":"Dr\u00e9no","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0087","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40257-021-00650-3","article-title":"Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase II study of the first triple-combination drug","volume":"23","author":"Stein Gold","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0088","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaad.2022.08.069","article-title":"Clindamycin phosphate 1.2%\/adapalene 0.15%\/benzoyl peroxide 3.1% gel for moderate-to-severe acne: efficacy and safety results from two randomized phase 3 trials","volume":"89","author":"Stein Gold","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0089","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/pde.15283","article-title":"Triple-combination clindamycin phosphate 1.2%\/benzoyl peroxide 3.1%\/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: randomized phase 2 study","volume":"40","author":"Eichenfield","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0090","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1994.12.6.1185","article-title":"Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study","volume":"12","author":"Cheng","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0091","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0092","series-title":"European Handbook of Dermatological Treatments","first-page":"3","article-title":"Acne","author":"Dessinioti","year":"2023"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0093","first-page":"442","article-title":"Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene","volume":"179","author":"Aubert","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0094","article-title":"Transcriptomics analysis indicates trifarotene reverses acne-related gene expression changes","volume":"8","author":"Dreno","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0095","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","article-title":"Randomized phase 3 evaluation of trifarotene 50 \u00b5g\/g cream treatment of moderate facial and truncal acne","volume":"80","author":"Tan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0096","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jdv.15794","article-title":"Long-term safety and efficacy of trifarotene 50 \u00b5g\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne","volume":"34","author":"Blume-Peytavi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0097","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s13555-023-01042-7","article-title":"Trifarotene reduces risk for atrophic acne scars: results from a phase 4 controlled study","volume":"13","author":"Schleicher","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0098","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.jaad.2022.12.053","article-title":"Teratogenic, unregulated, vitamin A acne supplements, and Roe v Wade: response to \u201cthe Supreme Court abortion ban impact on dermatology\u201d","volume":"88","author":"Zamil","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0099","article-title":"Risk of birth defects from vitamin A \u201cacne supplements\u201d sold online","volume":"11","author":"Zamil","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0100","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM199511233332101","article-title":"Teratogenicity of high vitamin A intake","volume":"333","author":"Rothman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.02.005_bib0101","doi-asserted-by":"crossref","first-page":"E376","DOI":"10.1001\/amajethics.2022.376","article-title":"Do you know how to assess risks posed by over-the-counter vitamin A supplements?","volume":"24","author":"Zamil","year":"2022","journal-title":"AMA J Ethics"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26000465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26000465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:40:28Z","timestamp":1774712428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0738081X26000465"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.02.005","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitamins and the skin: Vitamin A and retinoids in dermatology","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}